The Food and Drug Administration extended its review of Orexigen Therapeutics Inc.'s (Nasdaq: OREX) weight loss medication NB32. The stock price tumbled $1.16 to $5.64.
FDA extends review of Orexigen's NB32
June 11, 2014 at 12:52 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.